Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Clinical trial NCT04909515 · WITHDRAWN
Trial details
- NCT number
- NCT04909515
- Sponsor
- Y-mAbs Therapeutics
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-02
- Primary completion
- 2026-06-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.